Petros Pharmaceuticals (NASDAQ:PTPI) Issues Earnings Results

Petros Pharmaceuticals (NASDAQ:PTPIGet Free Report) posted its quarterly earnings data on Monday. The company reported ($2.17) earnings per share for the quarter, reports. The firm had revenue of ($0.36) million during the quarter. Petros Pharmaceuticals had a negative net margin of 181.87% and a negative return on equity of 97.67%.

Petros Pharmaceuticals Stock Down 23.6 %

Shares of PTPI stock opened at $1.07 on Wednesday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 2.71 and a current ratio of 3.02. The business has a 50 day moving average of $1.44 and a two-hundred day moving average of $1.43. Petros Pharmaceuticals has a 52 week low of $0.92 and a 52 week high of $9.54.

Wall Street Analyst Weigh In

Separately, Maxim Group began coverage on shares of Petros Pharmaceuticals in a research report on Friday, December 8th. They set a “buy” rating and a $4.00 price target on the stock.

Check Out Our Latest Research Report on Petros Pharmaceuticals

Hedge Funds Weigh In On Petros Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in PTPI. Renaissance Technologies LLC bought a new stake in Petros Pharmaceuticals during the second quarter worth approximately $34,000. Virtu Financial LLC bought a new stake in Petros Pharmaceuticals during the fourth quarter worth approximately $35,000. Schonfeld Strategic Advisors LLC bought a new stake in Petros Pharmaceuticals during the second quarter worth approximately $47,000. Vanguard Group Inc. raised its holdings in Petros Pharmaceuticals by 114.8% during the third quarter. Vanguard Group Inc. now owns 255,914 shares of the company’s stock worth $131,000 after purchasing an additional 136,773 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in Petros Pharmaceuticals by 880.2% during the first quarter. BlackRock Inc. now owns 191,715 shares of the company’s stock worth $300,000 after purchasing an additional 172,156 shares in the last quarter. 12.34% of the stock is currently owned by institutional investors and hedge funds.

About Petros Pharmaceuticals

(Get Free Report)

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).

Read More

Earnings History for Petros Pharmaceuticals (NASDAQ:PTPI)

Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.